Allosteric Antagonists Modulate Beta-1 Integrin for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating beta1 integrin function in tissue repair are limited by their reliance on understanding integrin states and domains, which can lead to different downstream signaling and functional outcomes, and beta1 integrin's existence in multiple splice variants complicates modulation, especially in reversing tissue injury and damage.
Innovation Solution
Development of allosteric antagonists that bind to beta1 integrin at distinct sites, altering its conformation to an intermediate affinity state, preventing activation and promoting tissue repair by maintaining ECM anchoring and reducing caspase activation and cell death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional methods modulate beta1 integrin by targeting specific domains or activation states, then integrin function can be altered, but different downstream signaling and functional outcomes occur, and the presence of multiple splice variants complicates the modulation process
Solution Approach 1:
The patent employs an allosteric antagonist as an intermediary molecule that binds to a site distinct from the ligand-binding domain of beta1 integrin. This mediator induces a conformational change in the integrin structure, transitioning it from an active high-affinity state to an inactive low-affinity state, thereby blocking ligand binding without requiring direct interaction with the ligand-binding domain itself.
Solution Approach 2:
The invention changes the conformational parameter of beta1 integrin by inducing a structural transition from the active extended conformation to the inactive bent conformation. This parameter change (conformational state) effectively switches the integrin's ligand-binding affinity from high to low, providing a mechanism to control integrin function through structural modification rather than through complex domain-specific interactions.
2Reliability
If beta1 integrin is activated to promote tissue repair, then cellular adhesion and signaling are enhanced, but tissue damage and cell death can occur due to excessive activation or inappropriate signaling
Solution Approach 1:
The allosteric antagonist exerts a preliminary anti-action by pre-blocking the integrin's active conformation before pathological activation can occur. By maintaining integrins in a low-affinity state, the compound prevents the excessive activation that would otherwise lead to harmful downstream signaling, cell death, and tissue damage, while still allowing controlled activation when needed for normal tissue repair processes.
Data Source
AI summary
The present invention provides methods and compositions which modulate beta 1 integrin activity by functioning as allosteric antagonists. In particular, the present invention provides methods for mediating tissue repair where insult or injury has occurred by antagonising the allosteric function of beta 1 integrin.